此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

2022年5月27日 更新者:Bristol-Myers Squibb

A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan

The purpose of this study is to determine the efficacy of Lenalidomide/Dexamethasone + Elotuzumab in the subjects with newly diagnosed, previously untreated Multiple Myeloma (MM) in Japan.

研究概览

研究类型

介入性

注册 (实际的)

82

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Kasama-shi、日本、3091793
        • Local Institution
    • Aichi
      • Nagoya-shi、Aichi、日本、4600001
        • Local Institution
      • Nagoya-shi、Aichi、日本、4678602
        • Local Institution
    • Aomori
      • Aomori-shi、Aomori、日本、0308553
        • Local Institution
    • Chiba
      • Chiba-shi、Chiba、日本、2608677
        • Local Institution
      • Kamogawa-shi、Chiba、日本、2968602
        • Local Institution
    • Ehime
      • Matsuyama-shi、Ehime、日本、7900024
        • Local Institution
    • Fukuoka
      • Fukuoka-shi、Fukuoka、日本、8128582
        • Local Institution
    • Gunma
      • Maebashi-shi、Gunma、日本、3718511
        • Local Institution
      • Shibukawa-shi、Gunma、日本、3770280
        • Local Institution
    • Hiroshima
      • Fukuyama-shi、Hiroshima、日本、7200001
        • Local Institution
    • Iwate
      • Morioka-shi、Iwate、日本、0208505
        • Local Institution
    • Kagoshima
      • Kagoshima-shi、Kagoshima、日本、8920853
        • Local Institution
    • Kyoto
      • Kyoto-shi、Kyoto、日本、6028566
        • Local Institution
    • Miyagi
      • Sendai、Miyagi、日本、9808574
        • Local Institution
    • Niigata
      • Niigata-shi、Niigata、日本、9518566
        • Local Institution
    • Okayama
      • Okayama-shi、Okayama、日本、7011192
        • Local Institution
    • Osaka
      • Osaka-shi、Osaka、日本、5438555
        • Local Institution
      • Osaka-shi、Osaka、日本、5300012
        • Local Institution
    • Saitama
      • Kawagoe-shi、Saitama、日本、3508550
        • Local Institution
    • Shizuoka
      • Hamamatsu-shi、Shizuoka、日本、4313192
        • Local Institution
    • Tochigi
      • Utsunomiya-shi、Tochigi、日本、3200834
        • Local Institution
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、1138677
        • Local Institution
      • Koto-ku、Tokyo、日本、1358550
        • Local Institution
      • Shibuya-ku、Tokyo、日本、1508935
        • Local Institution
      • Shinjuku-Ku、Tokyo、日本、1608582
        • Local Institution
      • Shinjuku-ku、Tokyo、日本、1628655
        • Local Institution
      • Tachikawa-shi、Tokyo、日本、1900014
        • Local Institution

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

20年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Newly diagnosed with symptomatic Multiple Myeloma (MM)
  • Have not received any prior systemic anti-myeloma therapy
  • Have measurable disease
  • Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old. There must be a comorbidity that prevents SCT for a subject < 65 years old

Exclusion Criteria:

  • Non-secretory myeloma
  • Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Active plasma cell leukemia
  • Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)

Drug: Lenalidomide

Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Drug: Dexamethasone

Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Biological: Elotuzumab (BMS-901608)

Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug

Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug

有源比较器:Arm B: Lenalidomide + Dexamethasone

Drug: Lenalidomide

Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug

Drug: Dexamethasone

Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld)
大体时间:From first dose until documented response (assessed up to February 2017, approximately 24 months)

ORR is the proportion of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or PR as determined by investigator using the International Myeloma Working Group (IMWG) response criteria.

SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

From first dose until documented response (assessed up to February 2017, approximately 24 months)

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:From first dose until documented response, up to approximately 72 months

ORR is the percentage of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) as determined by investigator using the International Myeloma Working Group (IMWG) response criteria.

SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required.

From first dose until documented response, up to approximately 72 months
Progression Free Survival (PFS)
大体时间:From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
PFS is defined as the time from randomization to the date of the first documented tumor progression, as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria, or to death due to any cause, provided death does not occur more than 10 weeks (2 or more assessment visits) after the last tumor assessment. Clinical deterioration will not be considered progression.
From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
Progression Free Survival (PFS) Rate
大体时间:From randomization up to the specified timepoints, up to 3 years
PFS rate is defined as the percentage of participants who have neither progressed nor died at the specified timepoints
From randomization up to the specified timepoints, up to 3 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2015年2月20日

初级完成 (实际的)

2017年2月9日

研究完成 (实际的)

2021年7月21日

研究注册日期

首次提交

2014年10月21日

首先提交符合 QC 标准的

2014年10月21日

首次发布 (估计)

2014年10月23日

研究记录更新

最后更新发布 (实际的)

2022年6月22日

上次提交的符合 QC 标准的更新

2022年5月27日

最后验证

2022年5月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅